Skip to main content
Top
Published in: Journal of Infection and Chemotherapy 5/2011

01-10-2011 | Original Article

Clinical and microbiological evaluation of hemodialysis-associated pneumonia (HDAP): should HDAP be included in healthcare-associated pneumonia?

Authors: Satoshi Kawasaki, Nobuki Aoki, Hiroshi Kikuchi, Hitoshi Nakayama, Noriko Saito, Hisaki Shimada, Shigeru Miyazaki, Shinji Sakai, Masashi Suzuki, Ichiei Narita

Published in: Journal of Infection and Chemotherapy | Issue 5/2011

Login to get access

Abstract

Although hemodialysis-associated pneumonia (HDAP) was included among the healthcare-associated pneumonias (HCAP) in the 2005 American Thoracic Society (ATS)/Infectious Diseases Society of America (IDSA) guideline, little information relevant to clinical epidemiology, especially microbiological characteristics, is available. This study aimed to reveal microbiological characteristics and clinical outcomes of HDAP and to assess whether HDAP should be included in the HCAP category. We retrospectively analyzed 69 HDAP patients [42 with moderate and 27 with severe disease based on A-DROP (age, dehydration, respiratory failure, orientation disturbance, and low blood pressure)] in whom sputum cultures were performed at our hospital between 2007 and 2009. The most common pathogens were Staphylococcus aureus (37.7%), which were composed of methicillin-resistant S. aureus (MRSA) (27.5%) and methicillin-sensitive S. aureus (MSSA) (10.1%), followed by Streptococcus pneumoniae (10.1%), Klebsiella pneumoniae (8.7%), Haemophilus influenzae (7.2%), and Moraxella catarrhalis (5.8%). This distribution mostly resembled the microbiological characteristics of HCAP reported previously, except that the frequency of multi-drug-resistant (MDR) gram negatives such as Pseudomonas aeruginosa (2.9%) was clearly lower and that of MRSA was higher. There were no significant differences in microbiological findings, including the incidence of MDR pathogens, between the two severity groups. Despite most cases (82.6%) receiving only monotherapy, the prognosis (30-day survival and in-hospital mortality rates were 88.4% and, 17.4%, respectively) was similar to the past HCAP reports, but there were no significant correlations between prognosis and presence of MDR pathogens (30-day mortality rates 18.2% in MDR positive vs. 8.5% in MDR negative; p = 0.242). Assessment for not only MDR pathogens, but also severity of illness by the A-DROP system made it possible to conduct stratification based on prognosis. Our results suggest that HDAP should be included in the HCAP category, while understanding that there are some differences.
Literature
1.
go back to reference Nakai S, Masakane I, Shigematsu T, Hamano T, Yamagata K, Watanabe Y, et al. An overview of regular dialysis treatment in Japan (As of 31 December 2007). Ther Apher Dial. 2009;13:457–504.PubMedCrossRef Nakai S, Masakane I, Shigematsu T, Hamano T, Yamagata K, Watanabe Y, et al. An overview of regular dialysis treatment in Japan (As of 31 December 2007). Ther Apher Dial. 2009;13:457–504.PubMedCrossRef
2.
go back to reference Muraya Y, Oozono Y, Kadota J, Miyazaki M, Hashimoto A, Iida K, et al. Clinical and immunological evaluation of infection in patients on Hemodialysis. J Infect Chemother. 1996;2:247–53.CrossRef Muraya Y, Oozono Y, Kadota J, Miyazaki M, Hashimoto A, Iida K, et al. Clinical and immunological evaluation of infection in patients on Hemodialysis. J Infect Chemother. 1996;2:247–53.CrossRef
3.
go back to reference Sarnak MJ, Jaber BL. Pulmonary infectious mortality among patients with end-stage renal disease. Chest. 2001;120:1883–7.PubMedCrossRef Sarnak MJ, Jaber BL. Pulmonary infectious mortality among patients with end-stage renal disease. Chest. 2001;120:1883–7.PubMedCrossRef
4.
go back to reference Committee for the Japanese Respiratory Society Guidelines for the Management of Respiratory Infections. The Japanese Respiratory Society guidelines for the management of community-acquired pneumonia in adults. Respirology. 2006;11:S79–133.CrossRef Committee for the Japanese Respiratory Society Guidelines for the Management of Respiratory Infections. The Japanese Respiratory Society guidelines for the management of community-acquired pneumonia in adults. Respirology. 2006;11:S79–133.CrossRef
5.
go back to reference Mandell LA, Wunderink RG, Anzueto A, Bartlett JG, Campbell GD, Dean NC, et al. Infectious Disease Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis. 2007;44:S27–72.PubMedCrossRef Mandell LA, Wunderink RG, Anzueto A, Bartlett JG, Campbell GD, Dean NC, et al. Infectious Disease Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis. 2007;44:S27–72.PubMedCrossRef
6.
go back to reference British Thoracic Society Research Committee. Community-acquired pneumonia in adults in British hospitals in 1982–1983: a survey of aetiology, mortality, prognostic factors, and outcome. Q J Med. 1987;62:195–220. British Thoracic Society Research Committee. Community-acquired pneumonia in adults in British hospitals in 1982–1983: a survey of aetiology, mortality, prognostic factors, and outcome. Q J Med. 1987;62:195–220.
7.
go back to reference Lim WS, van der Eerden MM, Laing R, Boersma WG, Karalus N, Town GI, et al. Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study. Thorax. 2003;58:377–82.PubMedCrossRef Lim WS, van der Eerden MM, Laing R, Boersma WG, Karalus N, Town GI, et al. Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study. Thorax. 2003;58:377–82.PubMedCrossRef
8.
go back to reference American Thoracic Society, Infectious Disease Society of America. Guidelines for the management of adults with hospital-acquired, ventilator- associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med. 2005;171:388–416.CrossRef American Thoracic Society, Infectious Disease Society of America. Guidelines for the management of adults with hospital-acquired, ventilator- associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med. 2005;171:388–416.CrossRef
9.
go back to reference Kollef MH, Marrow LE, Baughman RP, Craven DE, McGowan JE, Micek ST, et al. Health care-associated pneumonia (HCAP): a critical appraisal to improve identification, management, and outcomes-proceedings of the HCAP summit. Clin Infect Dis. 2008;46:296S–334S.CrossRef Kollef MH, Marrow LE, Baughman RP, Craven DE, McGowan JE, Micek ST, et al. Health care-associated pneumonia (HCAP): a critical appraisal to improve identification, management, and outcomes-proceedings of the HCAP summit. Clin Infect Dis. 2008;46:296S–334S.CrossRef
10.
go back to reference Kollef MH, Shorr A, Tabak YP, Gupta V, Liu LZ, Johannes RS. Epidemiology and outcome of health-care-associated pneumonia; results from a large US database of culture-positive pneumonia. Chest. 2005;128:3854–62.PubMedCrossRef Kollef MH, Shorr A, Tabak YP, Gupta V, Liu LZ, Johannes RS. Epidemiology and outcome of health-care-associated pneumonia; results from a large US database of culture-positive pneumonia. Chest. 2005;128:3854–62.PubMedCrossRef
11.
go back to reference Micek ST, Kollef KE, Reichley RM, Roubinian N, Kollef MH. Health care-associated pneumonia and community-acquired pneumonia: a single-center experience. Antimicrob Agents Chemother. 2007;51:3568–73.PubMedCrossRef Micek ST, Kollef KE, Reichley RM, Roubinian N, Kollef MH. Health care-associated pneumonia and community-acquired pneumonia: a single-center experience. Antimicrob Agents Chemother. 2007;51:3568–73.PubMedCrossRef
12.
go back to reference Shindo Y, Sato S, Maruyama E, Ohashi T, Ogawa M, Hashimoto N, et al. Health-care-associated pneumonia among hospitalized patients in Japanese community hospital. Chest. 2009;135:633–40.PubMedCrossRef Shindo Y, Sato S, Maruyama E, Ohashi T, Ogawa M, Hashimoto N, et al. Health-care-associated pneumonia among hospitalized patients in Japanese community hospital. Chest. 2009;135:633–40.PubMedCrossRef
13.
go back to reference Ishida T, Hashimoto T, Arita M, Ito I, Osawa M. Etiology of community-acquired pneumonia in hospitalized patients. 1998;114:1588–1593. Ishida T, Hashimoto T, Arita M, Ito I, Osawa M. Etiology of community-acquired pneumonia in hospitalized patients. 1998;114:1588–1593.
14.
go back to reference Woodhead M. Community-acquired pneumonia guideline-an international comparison: a view from Europe. Chest. 1998;113:183S–7S.PubMedCrossRef Woodhead M. Community-acquired pneumonia guideline-an international comparison: a view from Europe. Chest. 1998;113:183S–7S.PubMedCrossRef
15.
go back to reference Slinin Y, Foley RN, Collins AJ. Clinical epidemiology of pneumonia in hemodialysis patients: the USRDS waves 1, 3, and 4 study. Kidney Int. 2006;70:1135–41.PubMedCrossRef Slinin Y, Foley RN, Collins AJ. Clinical epidemiology of pneumonia in hemodialysis patients: the USRDS waves 1, 3, and 4 study. Kidney Int. 2006;70:1135–41.PubMedCrossRef
16.
go back to reference Guo H, Liu J, Collins AJ, Foley RN. Pneumonia in incident dialysis patients—the United States Renal Data System. Nephrol Dial Transplant. 2008;23:680–6.PubMedCrossRef Guo H, Liu J, Collins AJ, Foley RN. Pneumonia in incident dialysis patients—the United States Renal Data System. Nephrol Dial Transplant. 2008;23:680–6.PubMedCrossRef
17.
go back to reference Wakino S, Imai E, Yoshioka K, Kamayachi T, Minakuchi H, Hayashi K, et al. Clinical importance of Stenotrophomonas maltophilia nosocomial pneumonia due to its high mortality in hemodialysis patients. Ther Apher Dial. 2009;13:193–8.PubMedCrossRef Wakino S, Imai E, Yoshioka K, Kamayachi T, Minakuchi H, Hayashi K, et al. Clinical importance of Stenotrophomonas maltophilia nosocomial pneumonia due to its high mortality in hemodialysis patients. Ther Apher Dial. 2009;13:193–8.PubMedCrossRef
18.
go back to reference Duran N, Ocak S, Eskiocak AF. Staphylococcus aureus nasal carriage among the diabetic and non-diabetic haemodialysis patients. Int J Clin Pract. 2006;60:1204–9.PubMedCrossRef Duran N, Ocak S, Eskiocak AF. Staphylococcus aureus nasal carriage among the diabetic and non-diabetic haemodialysis patients. Int J Clin Pract. 2006;60:1204–9.PubMedCrossRef
19.
go back to reference Lederer SR, Riedelsdorf G, Schiffl H. Nasal carriage of meticillin resistant Staphylococcus aureus: the prevalence, patients at risk and the effect of elimination on outcomes among outclinic haemodialysis patients. Eur J Med Res. 2007;12:284–8.PubMed Lederer SR, Riedelsdorf G, Schiffl H. Nasal carriage of meticillin resistant Staphylococcus aureus: the prevalence, patients at risk and the effect of elimination on outcomes among outclinic haemodialysis patients. Eur J Med Res. 2007;12:284–8.PubMed
20.
go back to reference Aarts MA, Hancock JN, Heyland D, McLeod RS, Marshall JC. Empiric antibiotic therapy for suspected ventilator-associated pneumonia: a systematic review and meta-analysis of randomized trials. Crit Care Med. 2008;36:108–17.PubMedCrossRef Aarts MA, Hancock JN, Heyland D, McLeod RS, Marshall JC. Empiric antibiotic therapy for suspected ventilator-associated pneumonia: a systematic review and meta-analysis of randomized trials. Crit Care Med. 2008;36:108–17.PubMedCrossRef
21.
go back to reference Heyland DK, Dodek P, Mscedere J, Day A, Cook D. Randomized trial of combination versus monotherapy for the empiric treatment of suspected ventilator-associated pneumonia. Crit Care Med. 2008;36:737–44.PubMedCrossRef Heyland DK, Dodek P, Mscedere J, Day A, Cook D. Randomized trial of combination versus monotherapy for the empiric treatment of suspected ventilator-associated pneumonia. Crit Care Med. 2008;36:737–44.PubMedCrossRef
22.
go back to reference Brito V, Niederman MS. Healthcare-associated pneumonia is a heterogeneous disease, and all patients do not need the same broad-spectrum antibiotic therapy as complex nosocomial pneumonia. Curr Opin Infect Dis. 2009;22:316–25.PubMedCrossRef Brito V, Niederman MS. Healthcare-associated pneumonia is a heterogeneous disease, and all patients do not need the same broad-spectrum antibiotic therapy as complex nosocomial pneumonia. Curr Opin Infect Dis. 2009;22:316–25.PubMedCrossRef
Metadata
Title
Clinical and microbiological evaluation of hemodialysis-associated pneumonia (HDAP): should HDAP be included in healthcare-associated pneumonia?
Authors
Satoshi Kawasaki
Nobuki Aoki
Hiroshi Kikuchi
Hitoshi Nakayama
Noriko Saito
Hisaki Shimada
Shigeru Miyazaki
Shinji Sakai
Masashi Suzuki
Ichiei Narita
Publication date
01-10-2011
Publisher
Springer Japan
Published in
Journal of Infection and Chemotherapy / Issue 5/2011
Print ISSN: 1341-321X
Electronic ISSN: 1437-7780
DOI
https://doi.org/10.1007/s10156-011-0228-z

Other articles of this Issue 5/2011

Journal of Infection and Chemotherapy 5/2011 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine